Published in Vaccine on October 15, 2000
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer (2009) 3.06
Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol (2001) 1.73
Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol (2007) 1.68
Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci U S A (2007) 1.39
Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells. J Virol (2006) 1.26
Production and characterization of vaccines based on flaviviruses defective in replication. Virology (2006) 1.24
Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology (2008) 1.21
Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine (2010) 1.20
Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. J Virol (2011) 1.11
A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology (2008) 1.07
Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology (2010) 1.05
The Future of Smallpox Vaccination: is MVA the key? Med Immunol (2005) 1.04
The evolution of poxvirus vaccines. Viruses (2015) 1.02
Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection. J Virol (2009) 0.94
Japanese encephalitis: the virus and vaccines. Hum Vaccin Immunother (2013) 0.93
A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein. J Virol (2012) 0.85
A Systematic Review of Recent Advances in Equine Influenza Vaccination. Vaccines (Basel) (2014) 0.85
Differential induction of apoptosis, interferon signaling, and phagocytosis in macrophages infected with a panel of attenuated and nonattenuated poxviruses. J Virol (2014) 0.82
A selectable and excisable marker system for the rapid creation of recombinant poxviruses. PLoS One (2011) 0.82
Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease. Hum Vaccin Immunother (2017) 0.82
Vascular endothelial growth factor A promotes vaccinia virus entry into host cells via activation of the Akt pathway. J Virol (2012) 0.79
Construction and immune efficacy of recombinant pseudorabies virus expressing PrM-E proteins of Japanese encephalitis virus genotype І. Virol J (2015) 0.75
Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review. PLoS One (2016) 0.75
An enzyme-linked immunosorbent assay to characterize dengue infections where dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg (1989) 10.52
Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities. Arthritis Rheum (1977) 9.14
SWINE INFLUENZA : II. A HEMOPHILIC BACILLUS FROM THE RESPIRATORY TRACT OF INFECTED SWINE. J Exp Med (1931) 9.13
NEUTRALIZATION TESTS WITH SERA OF CONVALESCENT OR IMMUNIZED ANIMALS AND THE VIRUSES OF SWINE AND HUMAN INFLUENZA. J Exp Med (1936) 8.25
Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol (1989) 7.06
Neurological manifestations of dengue infection. Lancet (2000) 5.69
Early clinical and laboratory indicators of acute dengue illness. J Infect Dis (1997) 5.00
Etiology of interepidemic periods of mosquito-borne disease. Proc Natl Acad Sci U S A (2000) 4.75
Dengue virus structural differences that correlate with pathogenesis. J Virol (1999) 4.26
Neurologic abnormalities of Lyme disease. Medicine (Baltimore) (1979) 3.98
THE ETIOLOGY OF SWINE INFLUENZA. Science (1931) 3.88
AN INTERMEDIATE HOST FOR THE SWINE INFLUENZA VIRUS. Science (1939) 3.87
Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis (1999) 2.96
"MAD ITCH" OF CATTLE. Science (1930) 2.90
Japanese encephalitis. J Neurol Neurosurg Psychiatry (2000) 2.76
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg (2001) 2.67
Antibodies to the vitronectin receptor (integrin alpha V beta 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. J Virol (1995) 2.66
Two African viruses serologically and morphologically related to rabies virus. J Virol (1970) 2.62
Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J Virol (2001) 2.59
The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol Rev (1992) 2.56
Bunyaviridae. Intervirology (1980) 2.53
Extinction and rapid emergence of strains of dengue 3 virus during an interepidemic period. Virology (2002) 2.53
Thottapalayam virus: a presumptive arbovirus isolated from a shrew in India. Indian J Med Res (1971) 2.52
Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J Virol (1997) 2.51
Genetically engineered foot-and-mouth disease viruses with poly(C) tracts of two nucleotides are virulent in mice. J Virol (1993) 2.50
Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol (1990) 2.47
Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet (1998) 2.41
Oligonucleotide fingerprints of RNA species obtained from rhabdoviruses belonging to the vesicular stomatitis virus subgroup. J Virol (1977) 2.35
PSEUDORABIES AS A CONTAGIOUS DISEASE IN SWINE. Science (1934) 2.27
Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr Top Microbiol Immunol (2002) 2.18
HLA-A and -B allele associations with secondary dengue virus infections correlate with disease severity and the infecting viral serotype in ethnic Thais. Tissue Antigens (2002) 2.18
Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology (1991) 2.17
Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology (1992) 2.15
Use of recombinant envelope proteins for serological diagnosis of Dengue virus infection in an immunochromatographic assay. Clin Diagn Lab Immunol (2001) 2.09
The importance of inorganic phosphate in regulation of energy metabolism of Streptococcus lactis. J Biol Chem (1981) 2.05
High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. J Infect Dis (1999) 2.02
Detection of antibodies to alphaviruses by enzyme-linked immunosorbent assay. J Clin Microbiol (1979) 2.01
Protection against hepatitis A by an inactivated vaccine. JAMA (1994) 1.99
Proposed antigenic classification of registered arboviruses I. Togaviridae, Alphavirus. Intervirology (1980) 1.98
Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein. J Virol (1993) 1.97
Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol (1999) 1.94
Venezuelan haemorrhagic fever. Lancet (1991) 1.90
Impact of dengue virus infection on feeding behavior of Aedes aegypti. Am J Trop Med Hyg (1997) 1.90
Formation of recombinants between snowshoe hare and La Crosse bunyaviruses. J Virol (1977) 1.87
Epidemiological aspects of the 1969 yellow fever epidemic in Nigeria. Bull World Health Organ (1972) 1.86
Foot-and-mouth disease virus virulent for cattle utilizes the integrin alpha(v)beta3 as its receptor. J Virol (1998) 1.83
Genetic and antigenic diversity among eastern equine encephalitis viruses from North, Central, and South America. Am J Trop Med Hyg (1999) 1.83
Infectious Japanese encephalitis virus RNA can be synthesized from in vitro-ligated cDNA templates. J Virol (1992) 1.82
Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. J Infect Dis (1999) 1.82
Development of a fluorogenic RT-PCR system for quantitative identification of dengue virus serotypes 1-4 using conserved and serotype-specific 3' noncoding sequences. J Virol Methods (2001) 1.81
Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives. Chem Pharm Bull (Tokyo) (1993) 1.80
Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. J Med Virol (1999) 1.79
Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine (2001) 1.79
Evaluation of a dipstick enzyme-linked immunosorbent assay for detection of antibodies to dengue virus. Clin Diagn Lab Immunol (1997) 1.78
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Physiocochemical and serological studies. J Gen Virol (1971) 1.78
THE ANTIBODY RESPONSE TO SWINE INFLUENZA. J Exp Med (1939) 1.77
Molecular and epidemiologic analysis of dengue virus isolates from Somalia. Emerg Infect Dis (1998) 1.77
Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology (1992) 1.76
Rapid diagnosis of dengue viremia by reverse transcriptase-polymerase chain reaction using 3'-noncoding region universal primers. Am J Trop Med Hyg (1997) 1.75
Japanese encephalitis: immunocytochemical studies of viral antigen and inflammatory cells in fatal cases. Ann Neurol (1985) 1.73
Gamma interferon augments Fc gamma receptor-mediated dengue virus infection of human monocytic cells. J Virol (1988) 1.71
Nucleotide sequences and phylogeny of the nucleocapsid gene of Oropouche virus. J Gen Virol (2000) 1.70
Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya. Clin Infect Dis (1998) 1.69
Serotype-cross-reactive immunoglobulin M responses in dengue virus infections determined by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol (2000) 1.67
Electron microscopic and antigenic studies of uncharacterized viruses. II. Evidence suggesting the placement of viruses in the family Bunyaviridae. Arch Virol (1989) 1.67
Detection of hepatitis E virus infections among domestic swine in the Kathmandu Valley of Nepal. Am J Trop Med Hyg (1995) 1.67
Lysis of dengue virus-infected cells by natural cell-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity. J Virol (1984) 1.66
Mechanisms of hemorrhage in dengue without circulatory collapse. Am J Trop Med Hyg (2001) 1.65
Enhancement of platelet deposition by cross-linked hemoglobin in a rat carotid endarterectomy model. Circulation (1996) 1.65
An antiviral substance from Penicillium funiculosum. V. Induction of interferon by helenine. J Exp Med (1966) 1.63
Molecular evolution of dengue type 2 virus in Thailand. Am J Trop Med Hyg (1998) 1.63
Detection of La Crosse arbovirus antigen in mosquito pools: application of chromogenic and fluorogenic enzyme immunoassay systems. J Clin Microbiol (1982) 1.62
The predictive value of prostatic acid phosphatase as a screening test for prostatic cancer. N Engl J Med (1980) 1.61
The foot-and-mouth disease virus leader proteinase gene is not required for viral replication. J Virol (1995) 1.61
A CHANGE IN RABBIT FIBROMA VIRUS SUGGESTING MUTATION : III. INTERPRETATION OF FINDINGS. J Exp Med (1936) 1.61
Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. J Gen Virol (1989) 1.59
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies. J Gen Virol (1971) 1.56
Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes. J Virol (1989) 1.55
Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology (1991) 1.55
Genetic variation in yellow fever virus: duplication in the 3' noncoding region of strains from Africa. Virology (1996) 1.53
Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine (1996) 1.51
Antibody-dependent enhancement of dengue virus infection mediated by bispecific antibodies against cell surface molecules other than Fc gamma receptors. J Immunol (1991) 1.50
Multicentre evaluation of dengue IgM dot enzyme immunoassay. Clin Diagn Virol (1996) 1.49
Characterization of a highly attenuated Japanese encephalitis virus generated from molecularly cloned cDNA. J Infect Dis (1995) 1.46
Impaired T cell proliferation in acute dengue infection. J Immunol (1999) 1.46
Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis (1996) 1.45
Laboratory diagnosis of dengue virus infection by reverse transcriptase polymerase chain reaction (RT-PCR) and IgM-capture enzyme-linked immunosorbent assay (ELISA). Jpn J Infect Dis (1999) 1.44
Genetic determinants of altered virulence of Taiwanese foot-and-mouth disease virus. J Virol (2000) 1.44
Recurrence of Rift Valley fever in Egypt. Lancet (1993) 1.44
Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine (1994) 1.43